Development of Licensed Product Sample Clauses

The 'Development of Licensed Product' clause outlines the obligations and procedures for creating, improving, or commercializing a product that is covered by a license agreement. It typically specifies the responsibilities of the licensee regarding research, development milestones, timelines, and reporting requirements, and may include standards for diligence or performance. This clause ensures that the licensed technology or intellectual property is actively developed and brought to market, thereby protecting the interests of the licensor and maximizing the value of the licensed rights.
Development of Licensed Product. Alcon shall use best efforts to develop the Licensed Product for approval in the widest number of geographic markets consistent with the Development Plan and its overall product development strategy. Such development shall be pursued at Alcon's own expense. Alcon shall use its good faith business and scientific judgment as applied to commercial development projects, to allocate sufficient time, effort, equipment and facilities to carry out development of the Licensed Product. Alcon shall devote the same degree
View SourceView Similar (3)
Development of Licensed Product. 11.1 Commercially Reasonable Efforts. [**]
View SourceView Similar (2)
Development of Licensed Product. As between the Parties, Durect shall be solely responsible, at its own cost, expense and discretion, for designing, creating and finalizing a commercially reasonable plan for the development of Licensed Product sufficient to obtain Regulatory Approval of such product within the Territory, and then implementing and carrying out all activities contemplated under such development plan such as all research, development, scientific, medical, regulatory and other activities including, but limited to the design, production and/or implementation of all clinical studies, non-clinical studies, manufacturing process development, scale-up and validation, CMC activities, ICH registration batches, pre-approval inspection preparation, pharmaceutical development including quality control and stability, manufacturing, qualification and regulatory tasks. Notwithstanding the foregoing, Durect shall EpiCept License (final) use Commercially Reasonable Efforts to develop and commercialize Licensed Product throughout the Territory.
View SourceView Similar (2)
Development of Licensed Product. (s). ZAI shall use Commercially Reasonable Efforts to Develop the Licensed Product(s) to obtain Regulatory Approval in the Partner Territory, including but not limited to, using Commercially Reasonable Efforts to carry out Development (including Regulatory Activities as set forth in Section 5.4) of the Licensed Product(s) in accordance with the Partner Development Plan. ZAI shall have sole responsibility for resourcing and funding, and shall bear one hundred percent (100%) of the Development and Regulatory Costs with respect to the Development of the Licensed Product(s) for the Partner Territory. For clarity, ZAI shall have the right to conduct Development activities of the Licensed Product throughout the Development Territory for the purpose of obtaining Regulatory Approval of the Licensed Product in the Partner Territory, and ZAI shall bear the cost of such Development activities.
View Source
Development of Licensed Product. 4.1 Development of the Licensed Product. Threshold and Merck shall jointly and collaboratively Develop the Licensed Product in the Territory and conduct (either by themselves or through their respective Affiliates, agents or Third Party subcontractors) all Development activities (including Clinical Trials and non-clinical studies) to obtain Regulatory Approval for any Licensed Product in any Indication in the Territory in accordance with the Development Plan and the other terms of this Agreement. The Parties shall use Commercially Reasonable Efforts to diligently Develop the Licensed Product in accordance with the Development Plan and the other terms of this Agreement, it being understood that Threshold will be responsible for the Sarcoma Program as set forth in Article 4.6.
View Source
Development of Licensed Product. 5.01 PRODUCT DEVELOPMENT - Licensee shall be responsible, at its own cost and expense, for the development and commercialization of Licensed Product. Licensee shall use its *** to develop the Licensed Product. As used herein the term *** *** *** *** Licensee shall diligently perform or cause to be performed all research and development necessary to obtain and maintain in full force and effect Agency approval in *** *** *** *** Licensee shall at the earliest possible time, consistent with sound scientific and business principles, Cite applications for Agency approval to sell Licensed Products in *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the commission. 5.02 DEVELOPMENT SCHEDULE - Attached hereto as Exhibit B is an initial Development Schedule outlining the Licensed Product development plan for the United States market. The Development Schedule may be modified periodically as mutually agreed to, in writing, by the parties. Licensee's substantial compliance with the Development Schedule, as it may be amended from time to time, shall be deemed to satisfy the *** *** referred to in Section 5.01, above. 5.03 DATA TRANSFER - To the extent not provided during the term of the Option Agreement, Licensor shall provide Licensee with existing pre-clinical and clinical data. Such data will include the *** Licensor shall also provide reasonable technical assistance to facilitate an orderly transfer of the project, provided that such assistance shall not be at a level that is unduly burdensome to Licensor. At the request of Licensee, Licensor may, in its sole discretion, provide additional assistance at Licensee's expense. Promptly after the Effective Date, Licensor shall notify the FDA that Licensee has acquired exclusive rights to Licensed Product, and so should have access to relevant data relating to Licensed Product on file at the FDA. 5.04 PERIODIC UPDATES - Licensee will update Licensor in writing not less frequently than *** on the development status of the Licensed compound. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the commission.
View Source
Development of Licensed Product. ALCiS may, at ALCiS’ option, and at its sole cost and expense, advance the development of any Licensed Product, including, without limitation, the conduct of clinical trials (and the supply of clinical product therefor) and the preparation and submission of the NDA in order to obtain Regulatory Approval. BioZone shall cooperate in such efforts should ALCiS elect to proceed with such development.
View Source
Development of Licensed Product 
View SourceView Similar (5)

Related to Development of Licensed Product

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall ▇▇▇▇, and shall cause its Affiliates and Sublicensees to ▇▇▇▇, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.